Regenerx Biopharmaceuticals Inc Revenue Growth Rates (RGRX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Regenerx Biopharmaceuticals inc   (NONE: RGRX)
 

RGRX's Revenue Growth by Quarter and Year

Regenerx Biopharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RGRX Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 0.02
FY 0.02

RGRXs Annual Revenue
Regenerx Biopharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 0.08 millions
Regenerx Biopharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 0.08 millions
Regenerx Biopharmaceuticals Inc 's Revenue in the fiscal year 2020 $ 0.08 millions
Regenerx Biopharmaceuticals Inc 's Revenue in the fiscal year 2019 $ 0.08 millions
Regenerx Biopharmaceuticals Inc 's Revenue in the fiscal year 2018 $ 0.07 millions




RGRX Revenue first quarter 2023 Y/Y Growth Comment
Regenerx Biopharmaceuticals Inc reported decrease in Revenue in the first quarter 2023 by -4.05% to $ 0.02 millions, from the same quarter in 2022.
The decrease in the first quarter 2023 Regenerx Biopharmaceuticals Inc 's Revenue compares unfavorably to the Company's average Revenue growth of 2.06%.

Looking into first quarter 2023 results within Major Pharmaceutical Preparations industry 159 other companies have achieved higher Revenue growth. While Regenerx Biopharmaceuticals Inc ' s Revenue decline of -4.05% ranks overall at the positon no. 2573 in the first quarter 2023.


RGRX Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - 0 % 0 % 0 %
3rd Quarter September - 0 % 0 % 0 %
2nd Quarter June - 0 % 0 % 0 %
1st Quarter March -4.05 % 0 % 0 % 0 %
FY   - 0 % 0 % -

Financial Statements
Regenerx Biopharmaceuticals Inc 's first quarter 2023 Revenue $ 0.02 millions RGRX's Income Statement
Regenerx Biopharmaceuticals Inc 's first quarter 2022 Revenue $ 0.02 millions Quarterly RGRX's Income Statement


RGRX Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - 0 % 0 % 0 %
3rd Quarter September - 0 % 0 % 0 %
2nd Quarter June - 0 % 0 % 0 %
1st Quarter March -4.05 % 0 % 0 % 0 %
FY (Year on Year)   - 0 % 0 % -


Back to RGRX Growth rate Comparisons >> Back to RGRX Growth rate Comparisons >>


Revenue first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #160
Healthcare Sector #421
Overall #2573

Revenue Y/Y Growth Statistics
High Average Low
154.12 % 2.06 % -100 %
(Jun 30 2016)   (Mar 31 2014)
Revenue first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #160
Healthcare Sector #421
Overall #2573
Revenue Y/Y Growth Statistics
High Average Low
154.12 % 2.06 % -100 %
(Jun 30 2016)   (Mar 31 2014)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Regenerx Biopharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
446.33 % 7.49 % -100 %
(Mar 31 2016)  


RGRX's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2023 Regenerx Biopharmaceuticals Inc disclosed fall in Revenue from the fourth quarter by -4.05% to $ 0.02 millions, from $ 0.02 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 131 other companies have achieved higher Revenue quarter on quarter growth. While Regenerx Biopharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 2065.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #132
Healthcare Sector #355
Overall #2065
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #132
Healthcare Sector #355
Overall #2065
Revenue Q/Q Growth Statistics
High Average Low
446.33 % 7.49 % -100 %
(Mar 31 2016)  


RGRX's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2023 Regenerx Biopharmaceuticals Inc disclosed fall in Revenue from the fourth quarter by -4.05% to $ 0.02 millions, from $ 0.02 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 131 other companies have achieved higher Revenue quarter on quarter growth. While Regenerx Biopharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 2065.


Regenerx Biopharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)
Cumulative Revenue 12 Months Ending $ 0.08 $ 0.08 $ 0.08 $ 0.08 $ 0.08
Y / Y Revenue Growth (TTM) -0 % 0 % -0 % -0 % -0 %
Year on Year Revenue Growth Overall Ranking # 2685 # 2668 # 2222 # 2573 # 2587
Seqeuential Revenue Change (TTM) -0 % 0 % 0 % 0 % 0 %
Seq. Revenue Growth (TTM) Overall Ranking # 2686 # 2668 # 2340 # 2657 # 2516


Cumulative Revenue growth Comment
Regenerx Biopharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2022. If the fiscal year would end in Mar 31 2023, Regenerx Biopharmaceuticals Inc 's annual Revenue no change would be -0% year on year to $0 millions.

In the Healthcare sector 373 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2668 to 2685.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 142
Healthcare Sector # 374
Overall # 2685

Revenue TTM Y/Y Growth Statistics
High Average Low
53.94 %
 2.58 %
-42.69 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 142
Sector # 375
S&P 500 # 2686
Cumulative Revenue growth Comment
Regenerx Biopharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2022. If the fiscal year would end in Mar 31 2023, Regenerx Biopharmaceuticals Inc 's annual Revenue drop would be -0% year on year to $0 millions.

In the Healthcare sector 373 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2668 to 2685.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 142
Healthcare Sector # 374
Overall # 2685

Revenue TTM Y/Y Growth Statistics
High Average Low
53.94 %
2.58 %
-42.69 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 142
Sector # 375
S&P 500 # 2686




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RGRX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Mar 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2023
Regenerx Biopharmaceuticals inc -0.01%$ -0.005 millions
Community Health Systems Inc -0.10%$ -0.096 millions
West Pharmaceutical Services Inc -0.47%$ -0.472 millions
Butterfly Network Inc -0.63%$ -0.629 millions
Qhslab Inc -0.71%$ -0.712 millions
Waters Corporation-0.85%$ -0.854 millions
Dariohealth Corp -0.86%$ -0.856 millions
Fresenius Medical Care Ag-1.06%$ -1.058 millions
Acorda Therapeutics Inc -1.22%$ -1.225 millions
Baxter International Inc -1.56%$ -1.565 millions
Kymera Therapeutics Inc -1.62%$ -1.621 millions
Nature s Sunshine Products inc -1.68%$ -1.683 millions
Organon and Co -1.85%$ -1.851 millions
Scientific Industries Inc -2.08%$ -2.077 millions
Amgen Inc -2.13%$ -2.132 millions
Healthcare Services Group Inc -2.24%$ -2.245 millions
Adaptive Biotechnologies Corporation-2.52%$ -2.519 millions
Bristol myers Squibb Company-2.67%$ -2.670 millions
Caredx Inc -2.71%$ -2.712 millions
Biogen Inc -2.72%$ -2.717 millions
Innovage Holding Corp -2.72%$ -2.718 millions
Cardiff Lexington Corporation-2.73%$ -2.727 millions
Apyx Medical Corp-2.81%$ -2.810 millions
Avanos Medical Inc -2.89%$ -2.888 millions
Align Technology inc -3.09%$ -3.090 millions
Bio rad Laboratories Inc -3.32%$ -3.317 millions
Enhabit Inc -3.35%$ -3.354 millions
National Healthcare Corp-3.38%$ -3.377 millions
Thermogenesis Holdings Inc -3.42%$ -3.417 millions
Mesoblast Limited-3.58%$ -3.580 millions


About Regenerx Biopharmaceuticals Inc Revenue Growth Rates (RGRX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Regenerx Biopharmaceuticals Inc (CIK 707511).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001410578-23-001223
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Regenerx Biopharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.